tbuckley/cabot-search huggingface dataset:
Government Services
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Repurposing Cancer Drugs for COVID-19
Journal: Cancer Discovery (2020)

In the absence of specific therapeutic strategies for SARS-CoV-2, oncologists are exploring the potential of repurposing cancer drugs to treat COVID-19. For instance, androgen blockade with bicalutamide is being evaluated to tackle viral entry and replication, and it may be useful for patients with mild respiratory symptoms. Meanwhile, BTK inhibitors, such as acalabrutinib, could prove effective in mitigating severe, hyperinflammatory COVID-19.
HYPERVITAMINOSIS WITH VITAMIN D
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II study of FOLFOX combined with nab-paclitaxel (FOLFOX-A) in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: Big Ten Cancer Research Consortium—BTCRC-GI15-015.
Authors: Al Bowen Benson, Masha Kocherginsky, Pashtoon Murtaza Kasi, Nataliya Volodymyrivna Uboha, Emil Lou, Yolande Chen, Howard S. Hochster, Sheetal Mehta Kircher, Mary Frances Mulcahy
Journal: Journal of Clinical Oncology (2022)

283 Background: Doublet platinum or taxane-based therapies are the current standard backbone of treatment for advanced gastric/GEJ adenocarcinoma. Previously, anthracycline based triplets have been aborted due to lack of efficacy and toxicity. We hypothesize that the combination of FOLFOX and nab-paclitaxel (FOLFOX-A) will have a higher efficacy, a better tolerability, and enhanced patient reported outcomes. Methods: Phase II single arm trial of FOLFOX + nab-paclitaxel in chemotherapy–naïve unresectable, advanced gastric/GEJ adenocarcinoma. Nab-paclitaxel 150 mg/m2 · Oxaliplatin 85 mg/m2 · Leucovorin 400 mg/m2 · 5-FU 2400 mg/m2 over 46-48 hrs every 14 days. Primary objective was response rate.Evaluable disease according to RECIST v1.1 for solid tumors was required. Her-2 positive gastric tumor patients and those with clinically significant peripheral neuropathy were excluded. A Simon (1989), optimal two-stage design was employed. Response rates and Clopper-Pearson confidence intervals are reported. Progression free (PFS) and overall (OS) survival were estimated using the method of Kaplan-Meier. Results: A 29% response rate was observed in Stage 1 and therefore the study continued enrolling all planned 39 patients. Median age was 63 (range 20-80) years, 29 (74%) were male, 30 patients now are off treatment due to progression (17), initiation of alternative therapy (5) and side effects (3). 38 patients started treatment. Of the 35 patients evaluable for response, 14 (40.0%; 95%CI: 23.9% - 57.9%) had CR/PR as best response, with disease control rate of 80.0%. Progression-free (PFS) and overall survival (OS) were available for 36 patients, with median follow-up duration of 20 months (range: 1.9 - 34.45 months). Median PFS was 6.6 months (95%CI: 5.7 – 13.0), with 28.6% (95%CI: 15.2% - 53.9%) 12-month PFS rate. There were 21 deaths, median OS was 11.0 months (95%CI: 9.6 – 21.7), 12-month OS rate was 46.6% (95%CI: 30.9% - 70.3%). Treatment-related grade 3–4 toxicities included peripheral sensory neuropathy, anemia (18.4% each), decreased neutrophil count (15.8%), and diarrhea (7.9%). One patient died due to multi-organ failure, not treatment-related. 23 patients required dose reductions or discontinuation of at least 1 component of the 3-drug regimen due to toxicity. Median number of cycles completed was 4 (range: 0-30). Conclusions: FOLFOX-A has a significant response rate, expected toxicities, and should be considered for future investigation in combination with immunotherapy given the recent approvals.
Abnormal intraventricular flow velocities in patients with angina-like chest pain and angiographically normal coronary disease Hans Vandekerchkhove, Jozef Bartunek, Eddy Van Schuerbeeck, Linda Mortier, Benedicte Heyndrickx, Brian Roelandt, Koen Erard, Bernard De Bruyne. Cardiovascular Center, Aalst, Belgium
Journal: Journal of the American College of Cardiology (2001)
A novel inhibitory effect of adenosine on cardiac hypertrophy Masanori Asakura, Masafumi Kitakaze, Seiji Takashima, Shigeki Higashiyama, Yasuhiko Sakata, Hiroshi Asanuma, Shoji Sanada, Hisakazu Ogita, Yulin Liao, Koichi Node, Toshihiko Toyofuku, Tsunehiko Kuzuya, Michihiko Tada, Masatsugu Hori. Osaka University, Osaka, Japan
Journal: Journal of the American College of Cardiology (2001)
Analysis of 16S rRNA sequencing in advanced colorectal cancer tissue samples.
Authors: Hojung An, Mira A. Partha, Hojoon Lee, Billy Lau, Giwon Shin, Alison Figueroa Almeda, Hanlee P. Ji
Journal: Journal of Clinical Oncology (2022)

163 Background: Changes in the colon’s microbiota composition are contributors to the pathogenesis of colorectal cancer (CRC). Features of this microbiome may have prognostic significance. For this study, we analyzed 16S rRNA sequencing data from tumor tissue samples of advanced CRC patients and determined if there were potential correlations between microbiome composition and clinical outcomes. Methods: One hundred and thirty three advanced CRC patients in St. Vincent’s Hospital in Korea were enrolled. DNA was extracted from collected tissue samples, the V3-V4 regions were amplified, and a 16S rRNA gene amplicon library was prepared using an Illumina protocol. DNA was sequenced on an Illumina MiSeq instrument. We used three different bioinformatic packages to process the sequence data and evaluate the microbiome composition of each tumor. Results: The classification performances of three different analytic pipelines (Kraken2, QIIME2, and DADA2) were compared in a microbiome control sample. Among these, DADA2 and QIIME2 were chosen for use in subsequent analysis, due to their lower Chi-square (χ2) test statistic values on the control data. After excluding samples that retained less than 5% of total reads after merging, 120 samples were analyzed. The median age of the cohort was 63 years, 63.3% were male, and all were Korean. The distribution over primary sites was 27.5% from the right-side colon, 30.8% from the left-side colon, and 41.7% from the rectum. All subjects received the first line of systemic treatment. The median progression-free survival time was 8.9 months. Twenty-nine patients (24.2%) survived more than 24 months. When examining the results from the two bioinformatic packages, pairwise comparisons showed positive correlations in the relative abundances of the top 20 genera. Fusobacterium, a microbe known to relate to pathogenesis and prognosis of CRC, was not detected by QIIME2. Stratifying by primary site, rectal cancers showed higher alpha diversity than left- or right-side colon cancers. Separately, a higher serum CEA level (≥8) at diagnosis, and the presence of lung metastasis were both found to be related to higher alpha-diversity, a global indicator of microbiome composition. When excluding minimally abundant (&lt; 1% per patient) genera, beta-diversity was found to be differentiable by T stage, the presence of lung metastasis, and the presence of liver metastasis. Most notably, beta-diversity differed between patients who survived more than two years and patients who died within 2 years. Using the DADA2 results, we confirmed that the presence of Fusobacterium nucleatum in CRC tissue was found to be a strong predictor of poor overall survival (OS), along with old age and liver metastasis. Conclusions: This study suggests potential associations between microbiome composition and clinical parameters of advanced CRC. Microbial biomarkers may be a valuable prognostic tool in this population.
Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.
Authors: Thomas J. George, Greg Yothers, Samuel A. Jacobs, Gene Grant Finley, James Lloyd Wade, Caio Max Sao Pedro Rocha Lima, Jeffrey Scott Rose, Shalu Pahuja, Anuradha Krishnamurthy, John C. Krauss, Melvin Deutsch, Jesus C. Fabregas, James J. Lee, Carmen Joseph Allegra, Norman Wolmark
Journal: Journal of Clinical Oncology (2022)

99 Background: Although immunotherapy shows no benefit in microsatellite stable (MSS) colorectal cancer, preclinical models suggest that radiotherapy (RT) can enhance neoantigen presentation, modulate the microenvironment, and improve the likelihood of anti-tumor activity with checkpoint inhibitor use. Using a “window-of-opportunity” study design, this prospective phase II trial will determine the safety and activity of this approach with the anti-PD-L1 agent durvalumab (MEDI4736). Methods: Stage II/III patients (pts) with MSS rectal cancer undergoing standard NCCN guideline-compliant neoadjuvant chemoradiotherapy (CRT) followed by definitive surgery were eligible. Treatment included durvalumab (750mg IV infusion once every 2 wks) for 4 total doses beginning within 3-7 days after CRT completion followed by surgery within 8-12 wks of the final CRT dose. Primary end point (EP): Improvement in modified neoadjuvant rectal cancer (mNAR) score (goal 10.6) compared to historical controls (15.6) targeting a 20% DFS RR reduction and 3-4% absolute OS improvement. Secondary EPs: toxicity, pCR, cCR, therapy completion, negative surgical margins, sphincter preservation, and exploratory assessments of tumor-infiltrating lymphocytes, tumor Immunoscore, circulating immunologic profiles, and molecular predictors of response. We test H 0 : mNAR ≥15.6 vs H A : mNAR &lt;15.6 at alpha 0.10 one-sided with statistical significance defined as p&lt;0.1. Results: From May 2018 to October 2020, 45 pts were enrolled with 40 pts evaluable for mNAR. Mean mNAR was 12.03 (80% CI: 9.29-14.97) (p=0.06 one-sided). pCR=22.2%; cCR=31.1%; R0 resection=81.0%, and sphincter preservation=71.4%. Side effects were consistent with both CRT and durvalumab safety profile. Most common grade 3 AEs included diarrhea, lymphopenia, and back pain. There was one grade 4 AE (elevated amylase/lipase) and no grade 5 AEs. Remaining secondary and correlative immunologic end points are still being assessed. Conclusions: Durvalumab immediately following CRT prior to surgery for definitive management of rectal cancer was safe and without unexpected short-term toxicities. The primary end point of mean mNAR score was significantly less than our historical control, warranting further investigation. Correlative analyses for immunologic markers of response including PD-(L)1 expression and Immunoscore are ongoing. NCT 03102047. Support: AstraZeneca-Medimmune, NSABP Foundation. Clinical trial information: NCT03102047.
Double‐Network Hydrogel Armored Decellularized Porcine Pericardium as Durable Bioprosthetic Heart Valves
Authors: Si Cheng, Xianbao Liu, Yi Qian, Miribani Maitusong, Kaixiang Yu, Naifang Cao, Juan Fang, Feng Liu, Jinyong Chen, Dilin Xu, Gangjie Zhu, Tanchen Ren, Jian'an Wang
Journal: Advanced Healthcare Materials (2021)

Abstract Heart valves have extraordinary fatigue resistance which beat ≈3 billion times in a lifetime. Bioprosthetic heart valves (BHVs) made from fixed heteroplasm that are incrementally used in heart valve replacement fail to sustain the expected durability due to thrombosis, poor endothelialization, inflammation, calcification, and especially mechanical damage induced biocompatibility change. No effective strategy has been reported to conserve the biological properties of BHV after long‐term fatigue test. Here, a double‐network tough hydrogel is introduced, which interpenetrate and anchor into the matrix of decellularized porcine pericardium (dCell‐PP) to form robust and stable conformal coatings and reduce immunogenicity. The ionic crosslinked hyaluronic acid (HA) network mimics the glycocalyx on endothelium which improves antithrombosis and accelerates endothelialization; the chemical crosslinked hydrophilic polyacrylamide (PAAm) network further enhances antifouling properties and strengthens the shielding hydrogels and their interaction with dCell‐PP. In vitro and rabbit ex vivo shunt assay demonstrate great hemocompatibility of polyacrylamide/HA hydrogel hybrid PP (P/H‐PP). Cell experiments and rat subcutaneous implantation confirm satisfactory endothelialization, biocompatibility, and anticalcification properties. For hydrodynamic experiment, P/H‐PP gains full mark at different flow conditions and sustains excellent biomechanical and biological properties after 200 000 000 cycles. P/H double‐network hydrogel armoring dCell‐PP is a promising progress to extend BHV durability for clinical implantation therapy.
Diagnostic and therapeutic technology assessment. Gastric restrictive surgery for morbid obesity
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Committee on Insurance and Prepayment Plans. Guidelines for establishing medical society review committees
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mitral Regurgitation and MI Mortality
Authors: Kenneth G. Lehmann
Journal: Annals of Internal Medicine (1993)

Letters1 March 1993Mitral Regurgitation and MI MortalityKenneth G. Lehmann, MDKenneth G. Lehmann, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-5-199303010-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree that the number of patients with mitral regurgitation during evolving infarction was small and that definitive statements on pathogenesis, prognosis, or treatment should not be made from this study alone. However, the highly significant 1-year mortality differences attest to the strength of association between regurgitation and death [1]. Moreover, in the same issue of Annals, Tcheng and colleagues [2] noted strikingly similar rates of unadjusted mortality in a larger cohort of patients with acute infarction.The underlying mechanism relating mitral regurgitation and mortality remains perplexing. Most patients had mild regurgitation with no apparent effect on ventricular ...References1. Lehmann KG, Francis CK, Dodge HT, TIMI Study Group. Mitral regurgitation in early myocardial infarction. Ann Intern Med. 1992; 117:10-7. Google Scholar2. Tcheng JE, Jackman JD Jr, Nelson CL, Gardner LH, Smith LR, Rankin JS, et al. Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. Ann Intern Med. 1992; 117:18-24. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 March 1993Volume 118, Issue 5Page: 395-396KeywordsEjection fractionHemodynamicsInfarctionMitral insufficiencyMortalityPathogenesis ePublished: 15 August 2000 Issue Published: 1 March 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Polycystic ovary syndrome is associated with elevated central pulse pressure and increased proximal aortic stiffness Caren G. Solomon, Gary F. Mitchell, Nadia O. Skali, Rhonda Bentley-Lewis, Ellen W. Seely, James P. Sheehy, Scott D. Solomon, Andrea Dunaif. Brigham and Women's Hospital, Boston, MA, Cardiovascular Engineering Inc., Holliston, MA
Journal: Journal of the American College of Cardiology (2001)
Spotlight Issue on Growth Factors in the Vascular System
Journal: Cardiovascular Research (2004)

A spotlight issue on Growth Factors in the Vascular System is scheduled to appear in February, 2005.Growth factors have been identified as crucial mediators of vascular development and vascular growth.This is true for both physiological as well as pathological processes and includes the growth of new vessels, the growth of preformed collateral arteries, and also atherosclerosis and restenosis.Knowledge about the differential involvement of various growth factors and the activation of specific receptors and signalling pathways provides a basis for deeper insight into the biology of these processes.This insight, in turn, lays the foundation for growth factor therapies designed to stimulate collateral artery growth and to prevent restenosis.
Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
Authors: Sarah Frey, Teresa Po-Yu Chiang, Caoilfhionn M Connolly, Mayan Teles, Jennifer L Alejo, Brian J Boyarsky, Lisa Christopher-Stine, William A Werbel, Allan B Massie, Dorry L Segev, Julie J Paik
Journal: The Lancet Rheumatology (2022)
Receptor-Ribosome Coupling: A Link Between Extrinsic Signals and mRNA Translation in Neuronal Compartments
Authors: Max Koppers, Christine E. Holt
Journal: Annual Review of Neuroscience (2022)

Axons receive extracellular signals that help to guide growth and synapse formation during development and to maintain neuronal function and survival during maturity. These signals relay information via cell surface receptors that can initiate local intracellular signaling at the site of binding, including local messenger RNA (mRNA) translation. Direct coupling of translational machinery to receptors provides an attractive way to activate this local mRNA translation and change the local proteome with high spatiotemporal resolution. Here, we first discuss the increasing evidence that different external stimuli trigger translation of specific subsets of mRNAs in axons via receptors and thus play a prominent role in various processes in both developing and mature neurons. We then discuss the receptor-mediated molecular mechanisms that regulate local mRNA translation with a focus on direct receptor-ribosome coupling. We advance the idea that receptor-ribosome coupling provides several advantages over other translational regulation mechanisms and is a common mechanism in cell communication.
Plasma Exchange for COVID-19 Thrombo-Inflammatory Disease
Authors: Mari Thomas, Nishkantha Arulkumaran, David Brearley, Ferras Alwan, Deepak Singh, Michael P Lunn, Anna Welch, Samuel Clark, Eamon Raith, Ugan Reddy, Ryan Low, David Leverett, Mervyn Singer, Marie Scully
Journal: Blood (2020)
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
Authors: Constanze Kuhlmann, Carla Konstanze Mayer, Mathilda Claassen, Tongai Maponga, Wendy A Burgers, Roanne Keeton, Catherine Riou, Andrew D Sutherland, Tasnim Suliman, Megan L Shaw, Wolfgang Preiser
Journal: The Lancet (2022)